China National Medicines Corporation Ltd(600511) board of supervisors’ review opinions on the company’s 2021 annual report according to Article 82 of the securities law, the board of supervisors carefully reviewed the full text and summary of the company’s 2021 annual report, considered that the report was true and objective, fully revealed the overall operation of the company during the reporting period, agreed with the report, and put forward the following written review opinions: 1 The preparation and review procedures of the company’s 2021 annual report comply with laws, regulations, the articles of association and various provisions of the company’s internal management system;
2. The content and format of the company’s 2021 annual report comply with the provisions of China Securities Regulatory Commission and Shanghai Stock Exchange, and the information contained can truly reflect the company’s operation and management, financial status and cash flow of the current year from all aspects;
3. Before the board of supervisors put forward this opinion, it was not found that the personnel involved in the preparation and deliberation of the 2021 annual report had violated the confidentiality provisions;
4. All members of the board of supervisors guarantee that the information disclosed in the 2021 annual report of the company is true, accurate and complete, and promise that there are no false records, misleading statements or major omissions. Signature of Supervisor:
Liu Jingyun, Wu Ling
Zhou Xiaoya
China National Medicines Corporation Ltd(600511) March 16, 2022
